Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0
|
作者：
Gaber, Tarek [1 ]
Shippen, Clare [2 ]
机构：
[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England
[2] North West Deanery, Rehabil Med, Manchester, Lancs, England
来源：
PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期
关键词：
D O I：
10.1002/pnp.486
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [31] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [32] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Clavelou, Pierre
    Castelnovo, Giovanni
    Pourcher, Valerie
    De Seze, Jerome
    Vermersch, Patrick
    Ben-Amor, Ali-Frederic
    Savarin, Carine
    Defer, Gilles
    NEUROLOGY AND THERAPY, 2023, 12 (05) : 1457 - 1476
  • [33] Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S126 - S126
  • [34] Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
    Rauma, Ilkka
    Viitala, Matias
    Kuusisto, Hanna
    Atula, Sari
    Sipila, Jussi O. T.
    Ryytty, Mervi
    Soilu-Hanninen, Merja
    Jarvinen, Elina
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [35] Real world experience with cladribine tablets in the management of relapsing multiple sclerosis in Qatar
    Canibano, Beatriz Garcia
    Okar, Lina
    Baniamer, Yahya Zakarya
    Deleu, Dirk
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2024, 247
  • [36] COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
    Jack, Dominic
    Damian, Doris
    Nolting, Axel
    Galazka, Andrew
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [37] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
    Sorensen, P. S.
    Heick, A.
    Petersen, T.
    Joensen, H.
    Kopp, T. I.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
  • [38] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Pierre Clavelou
    Giovanni Castelnovo
    Valérie Pourcher
    Jerome De Sèze
    Patrick Vermersch
    Ali-Frederic Ben-Amor
    Carine Savarin
    Gilles Defer
    Neurology and Therapy, 2023, 12 : 1457 - 1476
  • [39] Real-World Outcomes With Cladribine Tablets in People With Relapsing Multiple Sclerosis
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Lebson, Lori
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1100 - 1100
  • [40] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306
12345